Abstract 19980: Comparison of Dabigatran and Rivaroxaban versus Warfarin in Patients With Persistent and Long-Standing Atrial Fibrillation Undergoing Electrical Cardioversion With High Risk of Stroke And Embolism

Introduction: The important factor for efficacy and safety for patients (pts) with atrial fibrillation (AF) undergoing electrical cardioversion (ECV) is appropriate use of oral anticoagulant (OAC). Hypothesis: Novel anticoagulants (NOAC) are a possible alternative OAC before and after ECV versus warfarin Methods: We have analysed the data before and after ECV in 2215 pts undergoing ECV. All pts had AF, 1718 persistent and 497 defined as long-standing, CHA2 DS2 VASc score was 3.6 ± 1.8, 1578 had one or two ECV previously. 1431 (64.6%) pts started the use of NOAC: dabigatran 490 pts 150 mg twice or 344 pts 110 mg twice or 597 rivaroxaban 20 mg daily before ECV for at least 21 day, 748 (35.4%) started warfarin therapy and 21 day start after INR was in range 2.0 - 3.0. 110 mg twice were prescribed for pts ≥ 75 year, HASBLEED ≥3 and chronic kidney disease. Transesophageal echocardiography (TEE) was encouraged before ECV in all pts with CHA2DS2VASc score ≥ 4, left atrial (LA) dilatation and AF duration ≥ 6 mont...